ONCY Oncolytics Biotech Inc.

1.37
-0.01  -1%
Previous Close 1.38
Open 1.28
Price To Book 13.7
Market Cap 51,203,784
Shares 37,090,525
Volume 195,899
Short Ratio
Av. Daily Volume 926,795
Stock charts supplied by TradingView

NewsSee all news

  1. Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update

    SAN DIEGO, California and CALGARY, Alberta, March 24, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today

  2. Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

    SAN DIEGO and CALGARY, Alberta, March 5, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its

  3. Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights

    SAN DIEGO and CALGARY, Alberta, Feb. 28, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it

  4. Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma

    SAN DIEGO and CALGARY, Alberta, Jan. 27, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that a

  5. Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer

    SAN DIEGO and CALGARY, Alberta, Jan. 22, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today stated that the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 interim data due at ASH December 5-8, 2020.
Pelareorep and Opdivo
Multiple myeloma
Phase 1b updated data to be presented at ESMO May 7-9, 2020 with final data due 2H 2020.
Pelareorep and Tecentriq - AWARE-1
Breast cancer
Phase 2 interim data due at ASCO May 29-June 2, 2020 with final data due 2H 2020.
Pelareorep with Keytruda
Pancreatic cancer
Phase 1 interim data due at ASCO 2020.
Pelareorep and Carfilzomib /Dexamethasone
Multiple myeloma
Phase 2 trial planned for 1Q 2020 with interim data due 4Q 2020 and final data 2H 2021.
Pelareorep, paclitaxel and avelumab - BRACELET-1
HR+ / HER2- breast cancer

Latest News

  1. Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update

    SAN DIEGO, California and CALGARY, Alberta, March 24, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today

  2. Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

    SAN DIEGO and CALGARY, Alberta, March 5, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its

  3. Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights

    SAN DIEGO and CALGARY, Alberta, Feb. 28, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it

  4. Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma

    SAN DIEGO and CALGARY, Alberta, Jan. 27, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that a

  5. Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer

    SAN DIEGO and CALGARY, Alberta, Jan. 22, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today stated that the

  6. Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma

    SAN DIEGO and CALGARY, Alberta, Jan. 13, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided a

  7. Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma

    SAN DIEGO and CALGARY, Alberta, Jan. 9, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that ROTH

  8. Oncolytics Biotech(R) Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / December 12, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  9. Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data Presented at the 61st Annual Meeting & Exposition of the American Society of Hematology

    Pre-clinical and clinical data demonstrate synergies between pelareorep and the proteasome inhibitor carfilzomib through inflammation, apoptosis and tumor responsesData provides scientific rationale supporting the

  10. Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / December 6, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  11. Oncolytics Biotech(R) Presents Clinical Data at the Fifth Annual Oncolytic Virotherapy Conference Highlighting Definitive Evidence of Systemic Delivery and Replication of Pelareorep in Tumor Tissue

    Pelareorep is the only oncolytic virus with meaningful clinical data demonstrating intravenous delivery and replication in tumor tissueSAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / December 3, 2019 / Oncolytics

  12. Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights

    Highlights positive synergies in CDK 4/6 inhibitor combination, as most recent data catalyst Management hosting conference call and webcast today at 5:00 pm ET SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 12,

  13. Oncolytics Biotech(R) Announces Exercise of Warrants

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 12, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  14. Oncolytics Biotech(R) Announces AWARE-1 Data Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

    Immuno-oncolytic virus replicates exclusively in tumor tissue and induces new T cell clonesDecrease in regulatory T cells leads to increased immune surveillance to fight cancerSAN DIEGO, CA and CALGARY, AB / ACCESSWIRE

  15. Oncolytics Biotech(R) Announces Abstract Published for the 61st Annual Meeting & Exposition of the American Society of Hematology

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 7, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  16. Oncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma

    Partial response of 17.4 months - beating historical overall survival dataT cell receptor sequencing revealed the creation of new T cell clones during treatment, which correlates with overall survival and is being

  17. Oncolytics Biotech(R) to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 5, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  18. Oncolytics Biotech(R) Provides Update on Partner Adlai Nortye's Clinical Progress

    Adlai received National Medical Products Administration approval for phase 3 clinical trials in ChinaSAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 31, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC),

  19. Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors

    Across 13 clinical studies and a broad range of cancers, up to 96 percent of tumor samples tested positive for replicating pelareorep virus after intravenous deliveryPelareorep is the only oncolytic virus with meaningful

  20. Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 1, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  21. Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 30, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  22. Oncolytics Biotech(R) Announces Upcoming Presentation at the 12th Annual International Oncolytics Virus Conference

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 25, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  23. Oncolytics Biotech(R) Announces Upcoming Conference Participation

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 23, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  24. Oncolytics Biotech(R) Receives Nasdaq Notification Letter

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 20, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  25. Oncolytics Biotech(R) to Present at the Ladenburg Thalmann Healthcare Conference

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 17, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today

  26. Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 5, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that

  27. Oncolytics Biotech(R) to Host Corporate Update Call to Discuss Recent Highlights and Expanded Catalysts and Milestones

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 4, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced it